Moderna (NASDAQ:MRNA) Upgraded to “Strong-Buy” at Hsbc Global Res

Hsbc Global Res upgraded shares of Moderna (NASDAQ:MRNA) from a hold rating to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.

A number of other equities research analysts also recently weighed in on MRNA. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. The Goldman Sachs Group decreased their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and dropped their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Bank of America decreased their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Finally, Barclays lowered their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and an average target price of $86.33.

Moderna Stock Up 7.2 %

Shares of MRNA opened at $39.51 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company has a 50-day simple moving average of $58.56 and a 200-day simple moving average of $96.68. Moderna has a 52 week low of $35.80 and a 52 week high of $170.47. The firm has a market capitalization of $15.20 billion, a P/E ratio of -6.79 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the firm posted ($1.39) EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, equities research analysts expect that Moderna will post -9.43 earnings per share for the current year.

Insider Activity

In related news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 13.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 2,930 shares of company stock valued at $217,170 over the last 90 days. 15.20% of the stock is owned by company insiders.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently made changes to their positions in the business. Commerzbank Aktiengesellschaft FI grew its stake in shares of Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after purchasing an additional 93 shares during the period. CVA Family Office LLC grew its holdings in shares of Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after buying an additional 96 shares during the period. Claro Advisors LLC increased its position in shares of Moderna by 2.0% in the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after buying an additional 108 shares in the last quarter. McAdam LLC raised its stake in Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after buying an additional 117 shares during the period. Finally, 180 Wealth Advisors LLC lifted its holdings in Moderna by 1.1% during the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after acquiring an additional 160 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.